Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 7/20 | 0.38 |
| ▸ | DRD3 | P35462 | 4/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DRD5 | P21918 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10648832 | 0.73 | HTT (0.43) | HTTL3MBTL1TSHRKDM4EDRD4 | |
| SCHEMBL14833178 | 0.71 | CYP19A1 (0.53) | HTTL3MBTL1TSHRKDM4EDRD4 | |
| SCHEMBL16051078 | 0.71 | SLC6A3 (0.31) | — | |
| SCHEMBL14804461 | 0.70 | KDM5B (0.48) | HTTL3MBTL1TSHRKDM4EDRD4 | |
| SCHEMBL317052 | 0.69 | CYP19A1 (0.50) | L3MBTL1TSHRALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL12068739 | 0.69 | HTT (0.44) | HTTL3MBTL1TSHRKDM4EDRD4 | |
| SCHEMBL15417776 | 0.69 | L3MBTL1 (0.44) | HTTL3MBTL1TSHRKDM4EDRD4 | |
| SCHEMBL28238594 | 0.69 | MAPT (0.50) | HTTL3MBTL1TSHRKDM4EDRD4 | |
| SCHEMBL16050493 | 0.68 | DAO (0.45) | — | |
| SCHEMBL16050368 | 0.68 | KDM4E (0.43) | L3MBTL1KDM4EHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | claimed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | claimed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | claimed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | claimed |
| EP-2970307-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | claimed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | claimed |
| CN-114007671-B | Methods and compositions for treating chronic inflammatory lesions, metaplasias, dysplasias, and cancers of epithelial tissue | 休斯敦大学体系 | 2024-06-14 | — | — | CN | disclosed |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | disclosed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | disclosed |
| CN-105980386-B | Pyrazolo compounds and uses thereof | 基因泰克公司 | 2021-08-13 | — | — | CN | disclosed |
| WO-2020219963-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| EP-2970307-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2015135094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | HTT 1874/4885L3MBTL1 2420/4885TSHR 4550/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | HTT 1874/4885L3MBTL1 2420/4885TSHR 4550/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | HTT 4764/4885L3MBTL1 3774/4885TSHR 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.